Contact

Payer

Pharma

Provider

Formulary guidance and transparency from P&T to point of care

MMIT Reality Check on Immunology: Rheumatoid Arthritis (Aug 2017)

Posted by Matt Breese on Aug 31, 2017

Find me on:

According to our recent payer coverage analysis for rheumatoid arthritis treatments, combined with news from key healthcare influencers, market access is shifting in this immunology drug landscape.

To help make sense of this new research, MMIT's team of experts analyzes the data and summarizes the key findings for you. The following are brief highlights. To read the full piece, including payer coverage, drug competition and prescriber trends, click here.

Payer Coverage: A market access snapshot for RA treatments shows the dominance of prior authorizations and step therapies. For the average pharmacy benefit life, access became slightly more restrictive for health exchange and medicare channels. 

mmit-reality-check-ra-q32017.png

Source: MMIT data as of Q3 2017

Trends:  With the biosimilar version of Remicade coming from Pfizer and Merck over the next 6 months, as well as the biosimilar Humira on the way, significant change is expected in this market. Many manufacturers invest in better understanding how pending auto substitute legislation will affect prescribing at the state level.

To read the full Reality Check on Rheumatoid Arthritis treatments with key findings on clinical characteristics, RA drug market access and payer coverage, please click on the button below: 

MMIT-RC_Thumbnail_1-1.png

View Reality Check

Topics: Specialty, Market Access, Branding & Marketing